Comparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes

NCT ID: NCT05921097

Last Updated: 2024-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-17

Study Completion Date

2024-07-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetic peripheral neuropathy is the most common complication to diabetes mellitus affecting as much as 50% of the population with diabetes. Symmetrical sensory neuropathy is by far the most common pattern, which often progress slowly over many years, although some individuals experience faster and more severe courses. Despite the frequent occurrence, the causes of diabetic peripheral neuropathy are largely unknown, which is reflected in the fact that no disease-modifying treatments are available for preventing, treating or even halting the progression of the disease. The consequences can be dire, as neuropathy frequently leads to foot ulcers, amputations or intolerable neuropathic pain in the lower extremities. Sensory loss may go completely undetected in diabetes, as there often are literally no symptoms. For many individuals, the development of diabetic peripheral neuropathy can therefore proceed completely unnoticed, making regular screening the most important tool for diagnosing the condition. Unfortunately, unlike nephropathy or retinopathy, diabetic peripheral neuropathy is not easily screened for, as the condition lacks reliable markers for early- or progressing disease. Therefore, screening for diabetic peripheral neuropathy currently revolves around diagnosing loss of protective sensation, judged by the inability to feel vibration or light touch. However, in their most recent guidelines, the American Diabetes Association has included screening for small fibre neuropathy using either the cold- and heat perception thresholds or pinprick as a clinical standard. Although this acknowledgement of the importance of assessing not only large- but also small nerve fibres is a huge step towards early detection of diabetic peripheral neuropathy, the overriding issue of insensitive, unreproducible, and inaccurate bedside tests for small nerve fibres remains. While cold- and heat perception and pinprick sensation are indeed mediated by small nerve fibres, the sensitivity of these methods, outside of extreme standardization only achievable in dedicated neuropathy research-centres, remain poor and not usable on an individual level. This lack of sensitivity has also become apparent in several large clinical trials, where the methods have continuously failed as robust clinical endpoints. Due to this, the hunt for a sensitive and reproducible method for adequate assessment of the small nerve fibres have begun. Amongst several interesting methods, two have gained particular interest (corneal confocal microscopy and skin biopsies with quantification of intra-epidermal nerve fiber density), due to their diverse strengths, although clinical application is currently limited to a few specialized sites. Furthermore, both methods suffer several inherent issues including that fact that they only provide information about the structure of the nerves and not the function. One method to assess the function of small cutaneous C-fibers is the assessment of the axon reflex flare response using laser doppler imaging (LDI) or Full-field laser perfusion imaging (FLPI), which has classically been studied using local heating. Unfortunately, this method is limited in clinical usage due to time-consumption. The investigators recently published an alternative method using a simple skin-prick application of histamine to evoke the response, which reduced the examination-time markedly. Before claiming the method to be a better alternative, the investigators do however need to prove that the method is as good as the original.

In addition to the direct comparison of the histamine-induced and the heating-induced axon-reflex flare response the study will also assess spatial acuity in the same cohort as a secondary aim. Spatial acuity is considered as a measure of the sensory systems ability to code spatial information regarding an external stimulus. To investigate the spatial acuity, the 2-point discrimination task (2PDT) is often used. Spatial acuity has been shown to be impaired in several chronic pain condition. Additionally, it has been shown that the 2PDT may be a useful tool to understand the sensory changes in diabetes\[8\].

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Diabetes Mellitus, Type 1 Diabetic Neuropathy Peripheral Small Fiber Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T1DM

People with type 1 diabetes

NC-Stat DPNCheck

Intervention Type DIAGNOSTIC_TEST

NC-Stat DPNCheck

QST

Intervention Type DIAGNOSTIC_TEST

QST

Biothesiometry

Intervention Type DIAGNOSTIC_TEST

Biothesiometry

Histamin-induced axon-reflex flare response

Intervention Type DIAGNOSTIC_TEST

Histamin-induced axon-reflex flare response

Local heating-induced axon-reflex flare response

Intervention Type DIAGNOSTIC_TEST

Local heating-induced axon-reflex flare response

2-point discrimination tasks

Intervention Type DIAGNOSTIC_TEST

2-point discrimination tasks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NC-Stat DPNCheck

NC-Stat DPNCheck

Intervention Type DIAGNOSTIC_TEST

QST

QST

Intervention Type DIAGNOSTIC_TEST

Biothesiometry

Biothesiometry

Intervention Type DIAGNOSTIC_TEST

Histamin-induced axon-reflex flare response

Histamin-induced axon-reflex flare response

Intervention Type DIAGNOSTIC_TEST

Local heating-induced axon-reflex flare response

Local heating-induced axon-reflex flare response

Intervention Type DIAGNOSTIC_TEST

2-point discrimination tasks

2-point discrimination tasks

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Quantitative Sensory Testing, thermal VPT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-75 years and diagnosed with type 1 diabetes

Exclusion Criteria

* Known critical limb ischemia (ankle-brachial index \< 50 mmHg or toe-brachial index \< 30 mmHg)
* Symptoms of claudicatio intermittens
* Inability to do without antihistamine for 24h prior to examination
* Known neurological disease (e.g., multiple sclerosis)
* Severe skin diseases on either foot (e.g., fulminant pemphigoid)
* Previous or current alcohol or drug abuse
* Previous or current chemotherapy or current disseminated cancer
* Known cause of neuropathy other than diabetes
* Previous amputation on either foot
* Active diabetic foot ulcer on either foot
* Pregnancy
* Inability to participate or other condition thought to impact the results (evaluated by investigator)
* Asymmetrical neuropathy (i.e., previous accident with radiating pain)
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aalborg University

OTHER

Sponsor Role collaborator

Aalborg University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Johan Bovbjerg Røikjer

Postdoc

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aalborg University Hospital

Aalborg, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N-20230007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.